Navigation Links
ATS Medical Expects Second Quarter Revenue of $16.7 to $16.9 Million
Date:7/7/2008

Revenue from non-mechanical heart valve businesses expected to grow over

150% from 2007 second quarter

MINNEAPOLIS, July 7 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today reported preliminary revenue results for the second quarter ended June 28, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

The Company currently expects revenue for the second quarter 2008 to be between $16.7 and $16.9 million, which would represent an increase of approximately 35% over second quarter 2007 revenue of $12.4 million and an increase of approximately 13% compared to the first quarter of 2008. Revenues from products and services other than the Company's mechanical heart valves are expected to exceed $6.0 million, an increase of approximately 18% over the previous quarterly record of $5.1 million set in the first quarter of 2008. The Company expects to release its second quarter results on August 4.

"Our second quarter results were driven by strong revenue growth across all of our product lines and geographies," said Michael Dale, Chairman, President and CEO of ATS Medical. "ATS CryoMaze(TM) surgical ablation revenue is expected to be especially strong, up approximately 220% over the prior year's second quarter and 13% compared to the first quarter of 2008. Revenue from our Heart Valve Therapy product offerings is expected to increase over 10% compared to the second quarter of 2007 and 11% compared to the first quarter of 2008, driven by new product introductions."

"While we continue to seek FDA approval of our ATS 3f(R) Aortic Bioprosthesis tissue valve, we have focused our commercial activities in a few select international markets. In the second quarter, these commercial efforts began to gain traction and we expect second quarter tissue valve revenue to increase approximately 90% compared to the first quarter of 2008. We continue to experience positive reception of our new ATS Open Pivot(R) AP360(TM) mechanical valve in the United States as evidenced by our third consecutive quarter of growth. We now expect a modest year-over-year increase in US mechanical valve revenue during the second quarter, the first such increase in five quarters. We believe that this quarter's results reflect our execution and the market's acceptance of our new product offerings across all segments," continued Mr. Dale.

"We also made significant progress recently in strengthening the Company's financial resources. We announced last week that Alta Partners had exercised its warrant for 1,960,000 shares of our common stock, generating $3.2 million in proceeds for the Company. In addition, we entered into a Subordinated Credit Agreement with Theodore C. Skokos, a member of our Board of Directors, for a two-year $5 million revolving line of credit. We continue to believe we do not need to raise additional capital to execute on our current growth plans," concluded Mr. Dale.

About ATS Medical

ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The Company, global in scope, is headquartered in Minneapolis, Minnesota. More than 150,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2007.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pennsylvania Medical Society and AARP Criticize Senator Specter for Blocking Bill to Protect Access to Doctors and Improve Medicare
2. AARP, Texas Medical Association Join Forces to Urge Passage of Bill Protecting Access to Doctors and Improving Medicare
3. Rising Medical Solutions, Inc. Expands Its California Managed Care Services to Include Utilization Review Program
4. Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud
5. Indiana State Medical Association and AARP Urge Reconsideration of Bill to Protect Seniors Access to Doctors and Improve Medicare
6. As I-1000 Signatures are Counted, Washington State Medical Association Opposition to Physician-Assisted Suicide Reiterated
7. VNUS Medical Technologies, Inc. Files Patent Infringement Lawsuits Against Biolitec, Dornier and CoolTouch
8. July 28, 2008: Status of Unlawfully Expelled Ahmadi Medical Students in Pakistan Still Unclear
9. ATS Medical to Participate at the Fourth Annual Collins Stewart Growth Conference
10. Breastfeeding.com Launches First Ever Social Network for Birth-Related Medical Professionals
11. New MagnaBloc™ Product Available from Gradient Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... Congratulations to Head Over Heels’ elite ... 12th. Ms. Esparza qualified into this prestigious status after winning the Vault, ... Vegas, Nevada. Frida is one of approximately 25 gymnasts in the nation who ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
(Date:2/23/2017)... CO (PRWEB) , ... February 23, 2017 , ... The ... announce the winner of the 2016 National Education Policy Center Bunkum Award. We invite ... reviewed in 2016. , This year’s Bunkum winner is the Center for American Progress ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease ... will be participating in Rare Disease Day events, hosted by the Rare Disease ... Disease Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews ...
(Date:2/23/2017)... Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... first two episodes of WE TV’s “Mama June: From Not to Hot,” which will ... TV notable, “Mama” June Shannon, known to millions from the 2012 reality television series, ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - 2016, provides ... research answers the following questions: What are ... they positioned in the Global Menopause market? What are ...
(Date:2/23/2017)... , Feb. 23, 2017 Research and ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... data and benchmarks in the global Fibromyalgia market. The ... the key drugs marketed for Fibromyalgia and their clinical attributes? How ...
(Date:2/23/2017)... 23, 2017 Obese people are ... for varicose veins in their body. The rising number ... the adoption of endovenous laser therapy for treatment of ... laser therapy market, published by Future Market Insights, ... and consequences of obesity have collectively factored the growth ...
Breaking Medicine Technology: